When scientists first discovered CRISPR, the possibilities for gene editing seemed endless. But challenges remain when it comes to actually translating that discovery into a therapy that works for ...
Scientists had tried to treat diseases by editing genes since the 1990s, but the methods were cumbersome and didn’t pay off. Then in June 2012, the journal Science published a paper by two future ...
CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results